Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Mary E. Law"'
Autor:
Mary E. Law, Bradley J. Davis, Amanda F. Ghilardi, Elham Yaaghubi, Zaafir M. Dulloo, Mengxiong Wang, Olga A. Guryanova, Coy D. Heldermon, Stephan C. Jahn, Ronald K. Castellano, Brian K. Law
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2022)
Tranexamic Acid (TA) is a clinically used antifibrinolytic agent that acts as a Lys mimetic to block binding of Plasminogen with Plasminogen activators, preventing conversion of Plasminogen to its proteolytically activated form, Plasmin. Previous stu
Externí odkaz:
https://doaj.org/article/5f7f9ec5aa3941a2b5245b8c17992f04
Autor:
Brian K. Law, Mary E. Law, Elham Yaaghubi, Amanda Ghilardi, Brad J. Davis, Renan Ferreira, Samantha Eggleston, Jade Nguyen, Grace Alexandrow, Jin Koh, Sixue Chen, Chi-Wu Chiang, Coy Heldermon, Peter Norgaard, Ronald K. Castallano, Zaafir M. Dulloo
Publikováno v:
Cancer Research. 83:6148-6148
Previous studies indicated that compounds termed Disulfide bond Disrupting Agents (DDAs) exhibit anti-cancer activity that is associated with downregulation of EGFR/HER1, HER2, and HER3, and activation of Death Receptors 4 and 5 (DR4/5). DDA-induced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ec72a8e596a48785196b89d7885df40
https://doi.org/10.1158/1538-7445.am2023-6148
https://doi.org/10.1158/1538-7445.am2023-6148
Autor:
Amanda F. Ghilardi, Elham Yaaghubi, Renan B. Ferreira, Mary E. Law, Yinuo Yang, Bradley J. Davis, Christopher M. Schilson, Ion Ghiviriga, Adrian E. Roitberg, Brian K. Law, Ronald K. Castellano
Publikováno v:
ChemMedChem. 17(14)
Reported are structure-property-function relationships associated with a class of cyclic thiosulfonate molecules-disulfide-bond disrupting agents (DDAs)-with the ability to downregulate the Epidermal Growth Factor Receptor (HER) family in parallel an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e9299246f4cb75a37a40561cb1fc958
https://pubmed.ncbi.nlm.nih.gov/35491396
https://pubmed.ncbi.nlm.nih.gov/35491396
Autor:
Michael C. Chung, Haiming Dai, Juan Guan, Jia Jia, Rui Kang, Scott H. Kaufmann, Mary E. Law, Brian K. Law, Daiqing Liao, X. Wei Meng, Gautam Sethi, Muthu K. Shanmugam, Xiaokun Shu, Daolin Tang, Tsz-Leung To, Mengxiong Wang, Kaiqin Ye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14ca8f4c5a72dcc5c92437519d6d7ee1
https://doi.org/10.1016/b978-0-12-814208-0.01002-2
https://doi.org/10.1016/b978-0-12-814208-0.01002-2
Autor:
Mary E. Law, Chi Wu Chiang, Sadie F. DePeter, Elham Yaaghubi, Sixue Chen, Peter Nørgaard, Bradley J. Davis, Christopher M. Schilson, Ronald K. Castellano, Brian K. Law, Renan B. Ferreira, Jin Koh, Coy D. Heldermon, Amanda F. Ghilardi
Publikováno v:
Law, M E, Yaaghubi, E, Ghilardi, A F, Davis, B J, Ferreira, R B, Koh, J, Chen, S, DePeter, S F, Schilson, C M, Chiang, C W, Heldermon, C D, Nørgaard, P, Castellano, R K & Law, B K 2022, ' Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death ', Cancer Letters, vol. 534, 215604 . https://doi.org/10.1016/j.canlet.2022.215604
Breast cancer mortality remains unacceptably high, indicating a need for safer and more effective therapeutic agents. Disulfide bond Disrupting Agents (DDAs) were previously identified as a novel class of anticancer compounds that selectively kill ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29acbb40a00907464bfc8ac10a6fd1a2
https://curis.ku.dk/ws/files/358644313/2021.01.13.426390v3.full.pdf
https://curis.ku.dk/ws/files/358644313/2021.01.13.426390v3.full.pdf
Publikováno v:
Mechanisms of Cell Death and Opportunities for Therapeutic Development ISBN: 9780128142080
Mechanisms of Cell Death and Opportunities for Therapeutic Development
Mechanisms of Cell Death and Opportunities for Therapeutic Development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ef7ce0adaf0e80299bc00358daaad6a
https://doi.org/10.1016/b978-0-12-814208-0.00006-3
https://doi.org/10.1016/b978-0-12-814208-0.00006-3
Autor:
Mary E. Law, Bradley J. Davis, Amanda F. Ghilardi, Elham Yaaghubi, Zaafir M. Dulloo, Mengxiong Wang, Olga A. Guryanova, Coy D. Heldermon, Stephan C. Jahn, Ronald K. Castellano, Brian K. Law
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2022)
Frontiers in Pharmacology, Vol 12 (2022)
Tranexamic Acid (TA) is a clinically used antifibrinolytic agent that acts as a Lys mimetic to block binding of Plasminogen with Plasminogen activators, preventing conversion of Plasminogen to its proteolytically activated form, Plasmin. Previous stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bef7ffd6bb6ed45854ea1cb5d8d955a
https://pubmed.ncbi.nlm.nih.gov/35095503
https://pubmed.ncbi.nlm.nih.gov/35095503
Autor:
Mary E. Law, Asif Raza, Timothy J. Garrett, Brian K. Law, Arun Sharma, Nayeong Koo, Iqbal Mahmud, Satya Narayan
SUMMARYThe treatment of colorectal cancer (CRC) with FOLFOX shows some efficacy, but these tumors quickly develop resistance to this treatment. We have observed an increased phosphorylation of AKT1/mTOR/4EBP1 and levels of p21 in FOLFOX-resistant CRC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7e208b01f58b8f8bd80aa0afd8ac966
https://doi.org/10.1101/2021.07.21.453259
https://doi.org/10.1101/2021.07.21.453259
Autor:
Mary E. Law, Brian K. Law, Ronald K. Castellano, Renan B. Ferreira, Mengxiong Wang, Bradley J. Davis, Elham Yaaghubi, Amanda F. Ghilardi, Chi Wu Chiang, Olga A. Guryanova, Coy D. Heldermon, Daniel Kopinke
Publikováno v:
Cell Death Discovery, Vol 5, Iss 1, Pp 1-15 (2019)
Cell Death Discovery
Cell Death Discovery
Disulfide bond-disrupting agents (DDAs) are a new chemical class of agents recently shown to have activity against breast tumors in animal models. Blockade of tumor growth is associated with downregulation of EGFR, HER2, and HER3 and reduced Akt phos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e52dcc29392ea12d61f42e6a1a07290
http://link.springer.com/article/10.1038/s41420-019-0228-9
http://link.springer.com/article/10.1038/s41420-019-0228-9
Autor:
Satya Narayan, Coy D. Heldermon, Renan B. Ferreira, Bonnie A. Avery, Chi Wu Chiang, Brian K. Law, Amanda F. Ghilardi, Elham Yaaghubi, Mary E. Law, Mengxiong Wang, Edgardo Rodriguez, Abhisheak Sharma, Bradley J. Davis, Ronald K. Castellano
Publikováno v:
Oncogene. 38:4264-4282
While HER2 and EGFR are overexpressed in breast cancers and multiple other types of tumors, the use of EGFR and/or HER2 inhibitors have failed to cure many cancer patients, largely because cancers acquire resistance to HER2/EGFR-specific drugs. Cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f401205dfda0c93609e96edec77cd8d8
https://doi.org/10.1038/s41388-019-0717-6
https://doi.org/10.1038/s41388-019-0717-6